摘要
背景与目的:基因多态预测肿瘤化疗药物敏感性对肿瘤个体化治疗具有重要意义。本研究旨在探讨DNA修复基因XRCC1 codon194及399位点基因多态性与非小细胞肺癌长春瑞滨加顺铂(vinorelbine and cisplatin,NVB and DDP,NP)方案化疗敏感性的关系。方法:采用聚合酶链反应-限制性片段长度多态性技术检测164例非小细胞肺癌患者外周血DNAXRCC1194和399位点的多态性。选择NP方案化疗,化疗两周期后评价疗效,并分析化疗敏感性与基因多态性的关系。结果:携带XRCC1基因Codon194C/T+T/T基因型者化疗有效率(41.8%)是C/C基因型者(26.0%)的2.038倍(P=0.036,95%CI=1.044-3.976)。携带XRCC1基因Codon399G/G、A/G、A/A型的患者化疗有效率(37.1%,34.6%,14.3%)之间的差异无统计学意义(P>0.05)。
Background and Objective. The gene polymorphism is used to predict the sensitivity of chemotherapy, which is significant for the individualized treatment of tumor. This study was to explore the correlation of codon 194 and codon 399 polymorphisms of DNA repair gene X-ray repair cross complementing （XRCC1） with the sensitivity of non-small cell lung cancer （NSCLC） to NP （vinorebine and cisplatin） chemotherapy. Methods： XRCC1 polymorphisms at codon 194 and codon 399 were detected in 164 patients with NSCLC using polymerase chain reaction restriction fragment length polymorphism （PCR-RFLP）. The haplotype of XRCC1 gene was analyzed using SHEsis analysis software. Patients treated with NP chemotherapy were evaluated after two periods of treatment, then the correlation of the sensitivity of chemotherapy with polymorphisms was analyzed. Results： The patients with the XRCC1 codon 194 C/I ＋T/T polymorphisms were 2.038 times as sensitive to the chemotherapy as the patients with C/C genotype （P=0.036, 95% CI：1.044-3.976）. The effective rate to chemotherapy was no significant difference between the patients with XRCC1 codon 399 G/G, A/G, and A/A polymorhism. The effective rate of chemotherapy of the patients with T-A haplotype significantly increased compared with those with other haplotype （P=0.031）, while that of the patients with C-A haplotype significantly decreased compared with others （P=0.035）. Conclusions： The sensitivity to NP chemotherapy significantly increased in the NSCLC patients with XRCC1 194 CT and -IT genotypes compared with those with CC genotype. XRCC1 codon 194 and codon 399 polymorphisms may be used to predict the sensitivity of NSCLC to NP chemotherapy.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2009年第12期1291-1297,共7页
Chinese Journal of Cancer
关键词
DNA修复基因
XRCC1
多态性
肺肿瘤
癌
非小细胞
NP方案
化疗敏感性
DNA repair gene
X-ray repair cross complementing 1（XRCC1）
polymorphism
lung neoplasm
non-small cell carcinoma
NP chemotherapy
chemotherapy sensitivity
